XENETIC BIOSCIENCES, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $3.0M | $2.5M | $2.5M | $1.7M | $1.2M | $436.9K | $17.1K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $3.1M | $3.3M | $3.5M | $4.8M | $3.2M | $1.7M | $4.9M |
| SG&A Expense | — | $2.7M | $3.4M | $3.6M | $3.7M | $3.7M | $3.4M | $4.7M |
| Operating Income | — | $-2.8M | $-4.2M | $-4.5M | $-6.7M | $-5.7M | $-13.9M | $-12.9M |
| Operating Margin | — | -95.2% | -168.2% | -177.8% | -393.6% | -495.1% | -3,189.8% | -75,511.7% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | $0 | $0 | $0 | $0 | $0 | $-2.9M | $0 |
| Net Income | — | $-2.7M | $-4.0M | $-4.1M | $-6.6M | $-5.6M | $-10.9M | $-12.8M |
| Net Margin | — | -90.1% | -158.4% | -162.8% | -383.9% | -486.4% | -2,493.1% | -74,856.6% |
| EPS (Basic) | — | $-1.58 | $-2.57 | $-2.71 | $-4.61 | $-0.55 | $-1.70 | $-6.33 |
| EPS (Diluted) | — | $-1.58 | $-2.57 | $-2.71 | $-4.61 | $-0.55 | $-1.70 | $-6.33 |
| Shares Outstanding (Basic) | 2.3M | 1.7M | 1.5M | 1.5M | 1.4M | 10.3M | 8.7M | 6.1M |
| Shares Outstanding (Diluted) | 2.3M | 1.7M | 1.5M | 1.5M | 1.4M | 10.3M | 8.7M | 6.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |